Study on Preventive Peptide Vaccine for Advanced ALK+ Lung Cancer

Inclusion Criteria

• Diagnosed with stage IV non-small cell lung cancer (NSCLC) or recurrent NSCLC that cannot be treated with standard therapies.
• Have a confirmed ALK gene rearrangement, identified through specific medical tests.
• Currently being treated with ALK-targeted drugs like crizotinib, ceritinib, alectinib, brigatinib, or lorlatinib, and have stable disease for at least four months.
• Do not have specific ALK resistance mutations that the vaccine targets.
• Have a performance status score of 0 or 1, indicating full activity or some restriction in strenuous activities.
• Are 18 years or older.

Exclusion Criteria

• Have another cancer that is progressing or has needed treatment in the past three years, except for certain skin cancers or other tumors treated successfully.
• Have received chemotherapy within 14 days before starting the vaccine or at the same time as the vaccine.
• Have received immunotherapy within 28 days before starting the vaccine or at the same time as the vaccine.
• Are on systemic immune suppression, including chronic oral or systemic steroids (except topical or inhaled steroids).
• Have symptomatic brain metastases or need increasing doses of steroids for brain issues within seven days before joining the study.
• Have current spinal cord compression, whether or not it causes symptoms, unless it is not causing any issues.